An FDA application for TAR-200 to treat BCG-unresponsive high-risk non-muscle-invasive bladder cancer is under real-time ...

A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus ...

The SunRISe-1 trial also assessed TAR-200 with cetrelimab and as monotherapy in different cohorts, focusing on safety and efficacy. The application is being submitted through the FDA’s Real-Time ...

Cetrelimab is under clinical development by Johnson & Johnson and currently in Phase III for Muscle Invasive Bladder Cancer (MIBC). According to GlobalData, Phase III drugs for Muscle Invasive Bladder ...

Ninety patients will be randomized to daily erdafitinib monotherapy versus combination erdafitinib + cetrelimab. The co-primary study endpoints are pathologic complete response and downstaging.

XOMA Royalty Corporation's portfolio includes riskier assets, impacting its stability. Find out why XOMA stock’s high-risk ...

Sasanlimab plus BCG improved outcomes in high-risk, BCG-naive non-muscle-invasive bladder cancer. Sasanlimab (PF-06801591) added to BCG therapy significantly improved outcomes for patients with ...